MAKE SURE YOUR DENTIST IS AN ADA MEMBER!: ADA Members Adhere to Strict Code of Ethics and Conduct. You should make sure you are SEEING AN ADA MEMBER DENTIST! Visit ADA Find-A-Dentist to Find One Near YOU
Ninth District Headquarters Office - Hawthorne, NY

2026 Ninth District President

Dr. Bharat Joshi

RENEW YOUR MEMBERSHIP TODAY!

3 EASY WAYS TO PAY 1 ONLINE: nysdental.org/renew 2 MAIL: Return dues stub and payment 3 PHONE: 1-800-255-2100
RENEW TODAY!

NYSDAPAC

NYSDA’s fully owned and operated Political Action Committee. With your support, NYSDAPAC will strengthen our political influence and ensure your voice is heard statewide and beyond.
Learn More

2026 Member Benefits Guide

Explore Your Member Benefits — The 2026 Member Benefits Guide is now available! See everything NYSDA offers and get a quick overview with our At-A-Glance one-pager.
VIEW BENEFITS

Member Assistance Program (MAP)

Life comes with challenges, but your new Member Assistance Program (MAP) is here to help. This FREE, CONFIDENTIAL benefit is available to you, your household, and your staff, offering resources and services to support mental health, reduce stress, and make life easier. Download the app today and get started.
LEARN MORE

Welcome to the Ninth District Dental Association

The Ninth District Dental Society was formed in 1909 and renamed to the Ninth District Dental Association in 2002. We have a membership of over 1500 dentists in 5 counties: Westchester, Rockland, Dutchess, Orange and Putnam.

In its quest to serve both the public and the profession, the Ninth District embodies the highest ideals.

The mission of the 9th District Dental Association is to serve and support its members and the public by improving the oral health of our community through Advocacy, Continuing Education and Camaraderie.

Latest News Around the Tripartite

FDA Issues Health Care Stakeholders Update

Apr 5, 2024

The United States Food and Drug Administration (FDA) has issued its weekly regulatory update for stakeholders.  You can read the FDA regulatory update for stakeholders below.

FDA Stakeholder Update Banner
April 5, 2024
Dear Colleague,
While the FDA continues to focus on protecting the public’s health, using science to guide our decisions, and facilitating access to critical medical products, we also recognize the work of our public health partners. As public health advocates, we know that your work to better our country is invaluable. Your partnership, knowledge and engagement in the public health space are appreciated.
2024 Happy Spring

 

Updates

Spotlight!

2024 National Minority Health Month
It’s National Minority Health Month and this year’s theme is “Be the Source for Better Health.” We invite everyone to be the source for clinical trial information.
Share our clinical trial resources, available in Spanish and other languages: https://www.fda.gov/.../minority.../clinical-trial-diversity  

Consumer Updates

Colorectal Cancer: What You Should Know About Screening
Colorectal Screening CU image
The evidence is clear - screening for colorectal cancer may save your life. Today, more and more people are choosing colorectal cancer screening. As a result, there is a steady decline in the number of older people getting and dying from colorectal cancer. Lower rates of smoking among Americans have also contributed to the decline in the past several years.
 
Is Food Safe if it Has Chemicals?
Is food safe graphic
You may have seen news or online content about chemicals in our foods. Perhaps you’re wondering, is a food safe to eat if it contains chemicals? All our food — like everything in the world — is made up of chemicals. The presence of a chemical alone isn’t what determines whether a food is safe to eat. 
 
Know Which Medication Is Right for Your Seasonal Allergies
close-up of a dandelion; woman sneezing; man rubbing his eyes
Seasonal allergic rhinitis, the medical term for seasonal allergies and hay fever, can also trigger or worsen asthma and lead to other health problems, such as sinus infections (sinusitis) and ear infections. The U.S. Food and Drug Administration regulates several medications that offer allergy relief.
 

Guidance Documents

Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
The purpose of this guidance is to provide recommendations to applicants and testing site management on achieving and maintaining data integrity for the clinical and bioanalytical portions of bioavailability (BA) and bioequivalence (BE) studies submitted in support of investigational new drug applications (INDs), new drug applications (NDAs), and abbreviated new drug applications (ANDAs), and the bioanalytical portion of clinical pharmacologic studies supporting CDER-regulated biologic license applications (BLAs) as well as amendments and supplements to these applications. 
Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements
This guidance expands upon and replaces the recommendations related to Master Files in the 2016 revised draft guidance (Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues). This approach of separating the 2016 revised draft guidance into discrete sections for ease of use is responsive to comments received from stakeholders. 
Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues
This draft guidance expands upon and replaces the recommendations related to Master Files for new dietary ingredient notifications (NDINs) in the 2016 revised draft guidance. For more information, see Constituent Update: FDA Issues Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements.
Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry
This guidance provides instructions for the electronic submission of expedited individual case safety reports (ICSRs) from investigational new drug (IND)-exempt bioavailability (BA)/bioequivalence (BE) studies conducted to support abbreviated new drug applications (ANDAs) to FDA Adverse Event Reporting System (FAERS). 
Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry
FDA is announcing the availability of a final guidance for industry entitled “Providing Regulatory Submissions in Electronic Format: IND Safety Reports.” This guidance finalizes the draft guidance of the same name published on October 30, 2019 (84 FR 58158), and describes the electronic format sponsors will be required to use when they electronically submit IND safety reports to CDER and CBER for serious and unexpected suspected adverse reactions, as required under 21 CFR 312.32(c)(1)(i).
View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.

Webinars and Virtual Workshops

Webinar - Draft Guidance: Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act
April 30, 2024; 1 - 2 p.m. ET
This draft guidance proposes updated recommendations to industry on cybersecurity considerations for cyber devices and for documentation in device premarket submissions. The Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, in its current form, remains the Agency's current thinking on this topic until this draft guidance is finalized, at which time the finalized version of Section II.
                                             Registration is not required.
FDA/CRCG Workshop: Considerations and Potential Regulatory Applications for a Model Master File
May 2 - 3, 2024
Day 1:  -  ET
Day 2:  -  ET
The purpose of this workshop is to engage stakeholders among model developers, industry, and FDA in a discussion on the concept, scope, and regulatory application of a Model Master File (MMF). 
 
View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts

About Us

The Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations. For more information, please contact us at: FDAStakeholderEngagement@fda.hhs.gov.

Latest News Around the Ninth

Around the Ninth District

Scarsdale Dental Society

This comprehensive course is designed for clinicians seeking to deepen expertise in managing patients, including those with complex systemic disease, head, and neck cancer histories, and those receiving antiresorptive or antiangiogenic therapies.
Add to:

NY-9DDS-Webinar: "Evaluating Third Molars"

Objectives: 1. To clinically and radiographically evaluate third molars 2. To determine the level of risk associated with extracting or leaving third molars. 3. To become fluent in communicating with the patient and specialist when dealing with third molars.
Add to:
Laurel Road Logo
avid traveling logo
Best Card Logo
AHI Logo
Volvo logo
UPS Logo
Thread Fellows
Mercedes-Benz Logo
Lenovo Logo
Lands' End Logo
HealthFirst Logo
GE Appliance Store Logo
Compliancy Group Logo
Care Credit Logo
Panacea Financial Logo
OnDiem